Established in 2016, a state-of-the-art R&D facility engaged in the development of Novel processes for Bu...
Established in 2016, a state-of-the-art R&D facility engaged in the development of Novel processes for Bulk Actives including Deuterated Actives, Advanced Intermediates and up the value chain. With experience, Anvitha Life Care Private Limited has knowledge and expertise as a leader in chemical research. Every decision is inspired by our main mission, which is to provide the highest standard of product and services to our clients. In this rapidly changing industry, we’ve realized the importance of continually updating our approach to stay relevant in the market, and are committed to just that.
Established in 2016, a state-of-the-art R&D facility engaged in the development of Novel processes for Bu...
Established in 2016, a state-of-the-art R&D facility engaged in the development of Novel processes for Bulk Actives including Deuterated Actives, Advanced Intermediates and up the value chain. With experience, Anvitha Life Care Private Limited has knowledge and expertise as a leader in chemical research. Every decision is inspired by our main mission, which is to provide the highest standard of product and services to our clients. In this rapidly changing industry, we’ve realized the importance of continually updating our approach to stay relevant in the market, and are committed to just that.
Embio is today the world’s second largest Integrated manufacturer of Ephedrine and Pseudoephedrine salt...
Embio is today the world’s second largest Integrated manufacturer of Ephedrine and Pseudoephedrine salts
Embio’s facility at Mahad ( 180 Kms from Bombay by road ) has been audited and approved by the Australian TGA, and the US FDA
Embio has also been granted the Certificate of Suitability ( CoS ) for its Pseudoephedrine HCl
The company was established in Taiwan in 1987 by the Swiss Siegfried Group with a history of more than 10...
The company was established in Taiwan in 1987 by the Swiss Siegfried Group with a history of more than 100 years. It is engaged in the research and development, production and marketing of intermediates, APIs and specialty chemicals. The products are exported to major pharmaceutical manufacturers in Europe, the United States, and Japan. Affirmed by customers. At present, the main shareholder of the company is the Sanshang Bank Group. The strong shareholder lineup and excellent management team have made the company's performance grow year by year, and it was listed on the Taiwan Stock Exchange in 2004.